胰腺癌患者血浆PAI-1测定的临床意义  

Determination of the Plasma PAI-1 and Its Clinical Significance in Pancreatic Cancer Patients

作　　者：钱璞[1] 卢志贤[1] 杨春香[1] 

机构地区：[1]无锡市第三人民医院,214041

出　　处：《放射免疫学杂志》2012年第5期559-560,共2页Journal of Radioimmanology

摘　　要：目的:探讨血浆纤溶酶原激活物抑制剂1(PAI-1)在胰腺癌患者中的浓度变化,并探讨在胰腺癌诊断中的应用价值。方法:收集胰腺癌患者50例,以及正常健康人50例,用ELISA检测胰腺癌患者及正常对照组血浆PAI-1的含量,并比较其差异。结果:胰腺癌组血浆PAI-1的含量(20.49±8.74)ng/ml明显高于正常对照组(P<0.01),且PAI-1浓度在胰腺癌Ⅳ期的含量与Ⅰ、Ⅱ、Ⅲ期比较均有不同程度升高(P<0.05)。结论:血浆中PAI-1的浓度升高与胰腺癌的发生有一定的联系,可作为诊断该类恶性肿瘤的实验室指标。Objective To investigate the concentration change of plasma plasminogen activator inhibitor-1（PAI-1） in patients with pancreatic cancer and its applicative value in the diagnosis.Methods The level of PAI-1 was measured（by ELISA） in 50 cases of pancreatic cancer and 50 cases of normal healthy people served as control,and compare the differences between the two groups.Results The level of PAI-1in pancreatic cancer patients（20.49±8.74 ng/ml） was significantly higher than the control group（P〈0.01）,the concentration of PAI-1in theⅣ stage was higher thanⅠ,Ⅱ andⅢ stage of pancreatic cancer.Conclusion The concentration of plasma PAI-1has some relationships with the development of pancreatic cancer,and can be used as a laboratory indicator in the diagnosis of such malignant tumor.

关 键 词：胰腺癌 纤溶酶原激活物抑制剂1 

分 类 号：R541.61[医药卫生—心血管疾病]